文献速递淋巴瘤

泊马度胺联合地塞米松治疗复发/难治性原发性中枢神经系统或玻璃体视网膜淋巴瘤的1期研究

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
PubMed 文献 · Blood · 2018-09-27

这项1期研究评估泊马度胺联合地塞米松治疗复发/难治性原发性中枢神经系统淋巴瘤和原发性玻璃体视网膜淋巴瘤,主要目标为确定泊马度胺最大耐受剂量。采用3例队列设计,泊马度胺3、5、7或10 mg口服每日一次连续21天每28天一个周期,地塞米松40 mg口服每周一次。最大耐受剂量为5 mg每日一次连续21天每28天一次。全研究总缓解率48%(12/25;95%CI 27.8%, 68.7%),最大耐受剂量队列总缓解率50%(8/16;95%CI 24.7%, 75.4%)。中位无进展生存期全研究5.3个月,缓解者9个月。

要点

  • 泊马度胺联合地塞米松在复发/难治性原发性中枢神经系统或玻璃体视网膜淋巴瘤中最大耐受剂量为5 mg每日一次连续21天每28天一次。
  • 全研究总缓解率48%(12/25),最大耐受剂量队列总缓解率50%(8/16)。
  • 中位无进展生存期全研究5.3个月,缓解者9个月。

核心结论

  • 泊马度胺联合地塞米松治疗复发/难治性原发性中枢神经系统淋巴瘤和原发性玻璃体视网膜淋巴瘤可行,并具有显著的治疗活性。

研究设计与样本

  • 1期研究,采用3例队列设计,剂量递增方案为泊马度胺3、5、7或10 mg口服每日一次连续21天每28天一个周期,地塞米松40 mg口服每周一次;2周期后泊马度胺单药维持直至疾病进展、不耐受或受试者退出;确定最大耐受剂量后扩展最大耐受剂量队列。
  • 29例患者中25例符合国际PCNSL协作组标准可评估,中位既往治疗3线。

主要发现

  • 泊马度胺最大耐受剂量为5 mg每日一次连续21天每28天一次。
  • 全研究总缓解率48%(12/25;95%CI 27.8%, 68.7%),包括6例完全缓解、2例未确认的完全缓解和4例部分缓解。
  • 最大耐受剂量队列总缓解率50%(8/16;95%CI 24.7%, 75.4%),包括5例完全缓解、1例未确认的完全缓解和2例部分缓解。
  • 中位无进展生存期全研究5.3个月,缓解者9个月。
  • 1例患者出现假性进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives. A cohorts-of-3 study design was used with a dose-escalation schedule consisting of POM (3, 5, 7, or 10 mg) orally daily for 21 days every 28 days and DEX 40 mg orally every week. After 2 cycles, POM was continued alone until disease progression, intolerance, or subject withdrawal. Following MTD determination, the MTD cohort was expanded. Twenty-five of 29 patients with the median of 3 prior treatments were eligible for assessment as per international PCNSL collaborative group criteria. The MTD of POM was 5 mg daily for 21 days every 28 days. Whole-study ORR was 48% (12 of 25; 95% confidence interval [CI], 27.8%, 68.7%) with 6 complete response (CR), 2 complete response, unconfirmed (CRu), and 4 partial response (PR). MTD cohort ORR was 50% (8 of 16; 95% CI, 24.7%, 75.4%) with 5 CR, 1 CRu, and 2 PR. Median PFS was 5.3 months (whole study) and 9 months (for responders). One patient had pseudoprogression. Grade 3/4 hematologic toxicities included neutropenia (21%), anemia (8%), and thrombocytopenia (8%). Grade 3/4 nonhematologic toxicities included lung infection (12%), sepsis (4%), fatigue (8%), syncope (4%), dyspnea (4%), hypoxia (4%), respiratory failure (8%), and rash (4%). POM/DEX treatment is feasible with significant therapeutic activity against relapsed/refractory PCNSL and PVRL. This trial was registered at www.clinicaltrials.gov as #NCT01722305.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018. PMID: 30262659. doi:10.1182/blood-2018-02-835496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。